Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective:
To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation.
To continue to assess the safety and tolerability throughout the study.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: DUPILUMAB
- drug: PLACEBO
Eligibility
Inclusion criteria:
Participants, male or female 18 years or older,
- with diagnosed chronic AD, demonstrated 1) inadequate response to topical medications,
2) expected severity of AD and 3) sleep disturbance.
- had applied skin emollients (moisturizers) at least 7 days before screening.
- had applied medium potency topical corticosteroids (TCS) on all active AD lesions at
least 7 days before screening.
- willed and able to comply with all clinic visits and study-related procedures.
- provided signed informed consent.
Exclusion criteria:
Participants excluded from the study:
- with known hypersensitivity to Dupixent, clinical depression, drug abuse history,
sleep problems not related to AD, irregular sleep pattern, active/acute infections,
severe medical conditions, laboratory abnormalities, any condition that might present
unreasonable risk to participants or interfered with study assessment, or any severe
concomitant illness(es) that would adversely affect the participant's participation in
the study, and contraindications of topical corticosteroids.
- at Baseline, presence of any conditions listed as criteria for study drug
discontinuation.
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective:
To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation.
To continue to assess the safety and tolerability throughout the study.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: DUPILUMAB
- drug: PLACEBO
Eligibility
Inclusion criteria:
Participants, male or female 18 years or older,
- with diagnosed chronic AD, demonstrated 1) inadequate response to topical medications,
2) expected severity of AD and 3) sleep disturbance.
- had applied skin emollients (moisturizers) at least 7 days before screening.
- had applied medium potency topical corticosteroids (TCS) on all active AD lesions at
least 7 days before screening.
- willed and able to comply with all clinic visits and study-related procedures.
- provided signed informed consent.
Exclusion criteria:
Participants excluded from the study:
- with known hypersensitivity to Dupixent, clinical depression, drug abuse history,
sleep problems not related to AD, irregular sleep pattern, active/acute infections,
severe medical conditions, laboratory abnormalities, any condition that might present
unreasonable risk to participants or interfered with study assessment, or any severe
concomitant illness(es) that would adversely affect the participant's participation in
the study, and contraindications of topical corticosteroids.
- at Baseline, presence of any conditions listed as criteria for study drug
discontinuation.
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective:
To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation.
To continue to assess the safety and tolerability throughout the study.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: DUPILUMAB
- drug: PLACEBO
Eligibility
Inclusion criteria:
Participants, male or female 18 years or older,
- with diagnosed chronic AD, demonstrated 1) inadequate response to topical medications,
2) expected severity of AD and 3) sleep disturbance.
- had applied skin emollients (moisturizers) at least 7 days before screening.
- had applied medium potency topical corticosteroids (TCS) on all active AD lesions at
least 7 days before screening.
- willed and able to comply with all clinic visits and study-related procedures.
- provided signed informed consent.
Exclusion criteria:
Participants excluded from the study:
- with known hypersensitivity to Dupixent, clinical depression, drug abuse history,
sleep problems not related to AD, irregular sleep pattern, active/acute infections,
severe medical conditions, laboratory abnormalities, any condition that might present
unreasonable risk to participants or interfered with study assessment, or any severe
concomitant illness(es) that would adversely affect the participant's participation in
the study, and contraindications of topical corticosteroids.
- at Baseline, presence of any conditions listed as criteria for study drug
discontinuation.
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective:
To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation.
To continue to assess the safety and tolerability throughout the study.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: DUPILUMAB
- drug: PLACEBO
Eligibility
Inclusion criteria:
Participants, male or female 18 years or older,
- with diagnosed chronic AD, demonstrated 1) inadequate response to topical medications,
2) expected severity of AD and 3) sleep disturbance.
- had applied skin emollients (moisturizers) at least 7 days before screening.
- had applied medium potency topical corticosteroids (TCS) on all active AD lesions at
least 7 days before screening.
- willed and able to comply with all clinic visits and study-related procedures.
- provided signed informed consent.
Exclusion criteria:
Participants excluded from the study:
- with known hypersensitivity to Dupixent, clinical depression, drug abuse history,
sleep problems not related to AD, irregular sleep pattern, active/acute infections,
severe medical conditions, laboratory abnormalities, any condition that might present
unreasonable risk to participants or interfered with study assessment, or any severe
concomitant illness(es) that would adversely affect the participant's participation in
the study, and contraindications of topical corticosteroids.
- at Baseline, presence of any conditions listed as criteria for study drug
discontinuation.
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective:
To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation.
To continue to assess the safety and tolerability throughout the study.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: DUPILUMAB
- drug: PLACEBO
Eligibility
Inclusion criteria:
Participants, male or female 18 years or older,
- with diagnosed chronic AD, demonstrated 1) inadequate response to topical medications,
2) expected severity of AD and 3) sleep disturbance.
- had applied skin emollients (moisturizers) at least 7 days before screening.
- had applied medium potency topical corticosteroids (TCS) on all active AD lesions at
least 7 days before screening.
- willed and able to comply with all clinic visits and study-related procedures.
- provided signed informed consent.
Exclusion criteria:
Participants excluded from the study:
- with known hypersensitivity to Dupixent, clinical depression, drug abuse history,
sleep problems not related to AD, irregular sleep pattern, active/acute infections,
severe medical conditions, laboratory abnormalities, any condition that might present
unreasonable risk to participants or interfered with study assessment, or any severe
concomitant illness(es) that would adversely affect the participant's participation in
the study, and contraindications of topical corticosteroids.
- at Baseline, presence of any conditions listed as criteria for study drug
discontinuation.
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective:
To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation.
To continue to assess the safety and tolerability throughout the study.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: DUPILUMAB
- drug: PLACEBO
Eligibility
Inclusion criteria:
Participants, male or female 18 years or older,
- with diagnosed chronic AD, demonstrated 1) inadequate response to topical medications,
2) expected severity of AD and 3) sleep disturbance.
- had applied skin emollients (moisturizers) at least 7 days before screening.
- had applied medium potency topical corticosteroids (TCS) on all active AD lesions at
least 7 days before screening.
- willed and able to comply with all clinic visits and study-related procedures.
- provided signed informed consent.
Exclusion criteria:
Participants excluded from the study:
- with known hypersensitivity to Dupixent, clinical depression, drug abuse history,
sleep problems not related to AD, irregular sleep pattern, active/acute infections,
severe medical conditions, laboratory abnormalities, any condition that might present
unreasonable risk to participants or interfered with study assessment, or any severe
concomitant illness(es) that would adversely affect the participant's participation in
the study, and contraindications of topical corticosteroids.
- at Baseline, presence of any conditions listed as criteria for study drug
discontinuation.
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting